{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:21:08Z","timestamp":1793496068635,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Britannia and Bial"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.parkreldis.2016.11.020","type":"journal-article","created":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T07:01:32Z","timestamp":1481266892000},"page":"S28-S35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"S1","title":["The efficacy of apomorphine \u2013 A non-motor perspective"],"prefix":"10.1016","volume":"33","author":[{"given":"Miguel","family":"Rosa-Grilo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubasher A.","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2016.11.020_bib1","first-page":"251","article-title":"Apomorphine in Parkinson's disease","volume":"56","author":"Schwab","year":"1951","journal-title":"Trans. Am. Neurol. Assoc."},{"issue":"8123","key":"10.1016\/j.parkreldis.2016.11.020_bib2","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S0140-6736(79)91725-2","article-title":"Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease","volume":"1","author":"Corsini","year":"1979","journal-title":"Lancet"},{"issue":"Pt 2","key":"10.1016\/j.parkreldis.2016.11.020_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/brain\/107.2.487","article-title":"On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study","volume":"107","author":"Hardie","year":"1984","journal-title":"Brain"},{"issue":"8582","key":"10.1016\/j.parkreldis.2016.11.020_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(88)91193-2","article-title":"Subcutaneous apomorphine in parkinsonian on-off oscillations","volume":"1","author":"Stibe","year":"1988","journal-title":"Lancet"},{"issue":"8622","key":"10.1016\/j.parkreldis.2016.11.020_bib5","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0140-6736(88)90860-4","article-title":"Subcutaneous apomorphine for on-off oscillations in Parkinson's disease","volume":"2","author":"Chaudhuri","year":"1988","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.parkreldis.2016.11.020_bib6","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events","volume":"58","author":"Dewey","year":"2001","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.020_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.parkreldis.2006.06.012","article-title":"Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease","volume":"13","author":"Pfeiffer","year":"2007","journal-title":"Park. Relat. Disord."},{"issue":"1\u20132","key":"10.1016\/j.parkreldis.2016.11.020_bib8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jns.2007.03.013","article-title":"Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose","volume":"258","author":"Pahwa","year":"2007","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.020_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/WNF.0b013e31816d91f9","article-title":"Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating \u201coff\u201d episodes in advanced Parkinson disease","volume":"32","author":"LeWitt","year":"2009","journal-title":"Clin. Neuropharmacol."},{"issue":"9","key":"10.1016\/j.parkreldis.2016.11.020_bib10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.parkreldis.2015.06.012","article-title":"D.\u00a0an expert consensus group for the use of apomorphine in Parkinson's, expert consensus group report on the use of apomorphine in the treatment of Parkinson's disease - clinical practice recommendations","volume":"21","author":"Trenkwalder","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.020_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/mds.20276","article-title":"Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges","volume":"20","author":"Katzenschlager","year":"2005","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.parkreldis.2016.11.020_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2165\/00002512-200421110-00001","article-title":"Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease","volume":"21","author":"Deleu","year":"2004","journal-title":"Drugs Aging"},{"issue":"12","key":"10.1016\/j.parkreldis.2016.11.020_bib13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1586\/14737175.2013.839235","article-title":"Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease","volume":"13","author":"Grandas","year":"2013","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"10.1016\/j.parkreldis.2016.11.020_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s100720170062","article-title":"Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results","volume":"22","author":"Stocchi","year":"2001","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.parkreldis.2016.11.020_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/WNF.0000000000000082","article-title":"Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses","volume":"38","author":"Bhidayasiri","year":"2015","journal-title":"Clin. Neuropharmacol."},{"issue":"7","key":"10.1016\/j.parkreldis.2016.11.020_bib16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1586\/14737175.2014.928202","article-title":"The role of subcutaneous infusion of apomorphine in Parkinson's disease","volume":"14","author":"Wenzel","year":"2014","journal-title":"Expert Rev. Neurother."},{"issue":"3","key":"10.1016\/j.parkreldis.2016.11.020_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-motor symptoms of Parkinson's disease: diagnosis and management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2016.11.020_bib18","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1038\/npjparkd.2015.13","article-title":"The range and nature of non-motor symptoms in drug-naive Parkinson's disease patients: a state-of-the-art systematic review","volume":"1","author":"Zis","year":"2015","journal-title":"NPJ Park. Dis."},{"issue":"11","key":"10.1016\/j.parkreldis.2016.11.020_bib19","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/mds.21586","article-title":"Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients","volume":"22","author":"Martinez-Martin","year":"2007","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2016.11.020_bib20","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/mds.22868","article-title":"The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire","volume":"25","author":"Chaudhuri","year":"2010","journal-title":"Mov. Disord."},{"issue":"Suppl 5","key":"10.1016\/j.parkreldis.2016.11.020_bib21","first-page":"33","article-title":"Early Parkinson's disease and non-motor issues","volume":"255","author":"Chaudhuri","year":"2008","journal-title":"J.\u00a0Neurol."},{"issue":"11\u201312","key":"10.1016\/j.parkreldis.2016.11.020_bib22","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1289\/ehp.1306967","article-title":"Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications","volume":"121","author":"Chen","year":"2013","journal-title":"Environ. Health Perspect."},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.020_bib23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mds.25799","article-title":"Nonmotor symptoms and health-related quality of life in early Parkinson's disease","volume":"29","author":"Martinez-Martin","year":"2014","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2016.11.020_bib24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/mds.25844","article-title":"Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease","volume":"29","author":"Berg","year":"2014","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.020_bib25","doi-asserted-by":"crossref","first-page":"e57221","DOI":"10.1371\/journal.pone.0057221","article-title":"A\u00a0proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need","volume":"8","author":"Ray Chaudhuri","year":"2013","journal-title":"PloS one"},{"issue":"3","key":"10.1016\/j.parkreldis.2016.11.020_bib26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.parkreldis.2014.12.031","article-title":"The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system","volume":"21","author":"Chaudhuri","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2016.11.020_bib27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/jnnp-2012-303455","article-title":"Parkinson's disease subtypes: lost in translation?","volume":"84","author":"Marras","year":"2013","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2016.11.020_bib28","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.parkreldis.2015.09.027","article-title":"Non motor subtypes and Parkinson's disease","volume":"22","author":"Sauerbier","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2016.11.020_bib29","first-page":"541","article-title":"Non-motor symptoms profile and burden in drug naive versus long-term Parkinson's disease patients","volume":"4","author":"Zis","year":"2014","journal-title":"J.\u00a0Park. Dis."},{"issue":"8","key":"10.1016\/j.parkreldis.2016.11.020_bib30","doi-asserted-by":"crossref","first-page":"e70244","DOI":"10.1371\/journal.pone.0070244","article-title":"The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients","volume":"8","author":"Erro","year":"2013","journal-title":"PloS one"},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.020_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.26077","article-title":"The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study)","volume":"30","author":"Pont-Sunyer","year":"2015","journal-title":"Mov. Disord."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2016.11.020_bib32","first-page":"S41","article-title":"Non motor subtypes and Parkinson's disease","volume":"22","author":"Sauerbier","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2016.11.020_bib33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/mds.23462","article-title":"The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease","volume":"26","author":"Martinez-Martin","year":"2011","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.parkreldis.2016.11.020_bib34","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.parkreldis.2011.02.018","article-title":"Parkinson's disease: the non-motor issues","volume":"17","author":"Chaudhuri","year":"2011","journal-title":"Park. Relat. Disord."},{"issue":"12","key":"10.1016\/j.parkreldis.2016.11.020_bib35","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.parkreldis.2013.08.012","article-title":"Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease","volume":"19","author":"Todorova","year":"2013","journal-title":"Park. Relat. Disord."},{"issue":"19","key":"10.1016\/j.parkreldis.2016.11.020_bib36","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1212\/WNL.0b013e3181c0d416","article-title":"International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease","volume":"73","author":"Martinez-Martin","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.020_bib37","first-page":"197","article-title":"Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect","volume":"1","author":"Martinez-Martin","year":"2011","journal-title":"J.\u00a0Park. Dis."},{"issue":"4","key":"10.1016\/j.parkreldis.2016.11.020_bib38","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26067","article-title":"EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease","volume":"30","author":"Martinez-Martin","year":"2015","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.parkreldis.2016.11.020_bib39","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40265-016-0600-5","article-title":"Psychosis in Parkinson's disease: epidemiology, pathophysiology, and management","volume":"76","author":"Chang","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.parkreldis.2016.11.020_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.parkreldis.2016.04.023","article-title":"Parkinson's disease, visual hallucinations and apomorphine: a review of the available evidence","volume":"27","author":"Borgemeester","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2016.11.020_bib41","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.23659","article-title":"Neuropathologic substrates of Parkinson disease dementia","volume":"72","author":"Irwin","year":"2012","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2016.11.020_bib42","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/jnnp.54.4.372","article-title":"Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment","volume":"54","author":"Ray-Chaudhuri","year":"1991","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.020_bib43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1353-8020(97)00009-6","article-title":"Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment","volume":"3","author":"Ellis","year":"1997","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2016.11.020_bib44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.parkreldis.2009.05.006","article-title":"Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations","volume":"16","author":"van Laar","year":"2010","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2016.11.020_bib45","first-page":"579","article-title":"A\u00a05-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation","volume":"258","author":"Antonini","year":"2011","journal-title":"J.\u00a0Neurol."},{"issue":"8","key":"10.1016\/j.parkreldis.2016.11.020_bib46","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/mds.22063","article-title":"Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study","volume":"23","author":"Garcia Ruiz","year":"2008","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2016.11.020_bib47","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mds.26422","article-title":"Apomorphine: a potential modifier of amyloid deposition in Parkinson's disease?","volume":"31","author":"Yarnall","year":"2016","journal-title":"Mov. Disord."},{"issue":"4341","key":"10.1016\/j.parkreldis.2016.11.020_bib48","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1126\/science.347574","article-title":"Schizophrenic symptoms improve with apomorphine","volume":"200","author":"Tamminga","year":"1978","journal-title":"Science"},{"issue":"8637","key":"10.1016\/j.parkreldis.2016.11.020_bib49","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0140-6736(89)90116-5","article-title":"Side-effects of subcutaneous apomorphine in Parkinson's disease","volume":"1","author":"Ruggieri","year":"1989","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.parkreldis.2016.11.020_bib50","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/jnnp.52.4.544","article-title":"Subcutaneous apomorphine in Parkinson's disease","volume":"52","author":"Pollak","year":"1989","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"823","key":"10.1016\/j.parkreldis.2016.11.020_bib51","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/pgmj.70.823.344","article-title":"Subcutaneous apomorphine infusion in Parkinson's disease: does it have a role?","volume":"70","author":"Muhiddin","year":"1994","journal-title":"Postgrad. Med. J."},{"issue":"3","key":"10.1016\/j.parkreldis.2016.11.020_bib52","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1750-3639.2009.00369.x","article-title":"The epidemiology of dementia associated with Parkinson's disease","volume":"20","author":"Aarsland","year":"2010","journal-title":"Brain Pathol."},{"issue":"6","key":"10.1016\/j.parkreldis.2016.11.020_bib53","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/jnnp-2011-301874","article-title":"Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease","volume":"83","author":"Poletti","year":"2012","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.020_bib54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/mds.26016","article-title":"Clinical spectrum of impulse control disorders in Parkinson's disease","volume":"30","author":"Weintraub","year":"2015","journal-title":"Mov. Disord."},{"issue":"15","key":"10.1016\/j.parkreldis.2016.11.020_bib55","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1212\/WNL.0000000000002001","article-title":"Longitudinal study of normal cognition in Parkinson disease","volume":"85","author":"Pigott","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.parkreldis.2016.11.020_bib56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.parkreldis.2011.08.010","article-title":"Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications","volume":"18","author":"Drapier","year":"2012","journal-title":"Park. Relat. Disord."},{"issue":"12","key":"10.1016\/j.parkreldis.2016.11.020_bib57","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/mds.20237","article-title":"Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease","volume":"19","author":"Alegret","year":"2004","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2016.11.020_bib58","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/jnnp.2005.078659","article-title":"Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus","volume":"77","author":"De Gaspari","year":"2006","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.020_bib59","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.22319","article-title":"Apomorphine treatment in Alzheimer mice promoting amyloid-beta degradation","volume":"69","author":"Himeno","year":"2011","journal-title":"Ann. Neurol."},{"issue":"Suppl 2","key":"10.1016\/j.parkreldis.2016.11.020_bib60","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/j.parkreldis.2015.10.225","article-title":"Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease: effects on motor and non motor symptoms with brain metabolism correlations","volume":"22","author":"Auffret","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2016.11.020_bib61","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00455-015-9671-9","article-title":"Dysphagia in Parkinson's disease","volume":"31","author":"Suttrup","year":"2016","journal-title":"Dysphagia"},{"issue":"1","key":"10.1016\/j.parkreldis.2016.11.020_bib62","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00455-008-9180-1","article-title":"Effects of therapy for dysphagia in parkinson's disease: systematic review","volume":"24","author":"Baijens","year":"2009","journal-title":"Dysphagia"},{"issue":"6","key":"10.1016\/j.parkreldis.2016.11.020_bib63","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/mds.870110622","article-title":"Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease","volume":"11","author":"Tison","year":"1996","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2016.11.020_bib64","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/jnnp.63.5.579","article-title":"Response of parkinsonian swallowing dysfunction to dopaminergic stimulation","volume":"63","author":"Hunter","year":"1997","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.parkreldis.2016.11.020_bib65","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/archneur.1989.00520460037010","article-title":"Anal sphincter dysfunction in Parkinson's disease","volume":"46","author":"Mathers","year":"1989","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.parkreldis.2016.11.020_bib66","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.410330512","article-title":"Defecatory function in Parkinson's disease: response to apomorphine","volume":"33","author":"Edwards","year":"1993","journal-title":"Ann. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.parkreldis.2016.11.020_bib67","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2011.10.025","article-title":"Sleep disorders in Parkinson's disease: many causes, few therapeutic options","volume":"314","author":"Diederich","year":"2012","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"3","key":"10.1016\/j.parkreldis.2016.11.020_bib68","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1600-0404.1999.tb00732.x","article-title":"Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome","volume":"100","author":"Reuter","year":"1999","journal-title":"Acta Neurol. Scand."},{"issue":"3","key":"10.1016\/j.parkreldis.2016.11.020_bib69","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10072-003-0133-z","article-title":"Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment","volume":"24","author":"Priano","year":"2003","journal-title":"Neurol. Sci."},{"issue":"5","key":"10.1016\/j.parkreldis.2016.11.020_bib70","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mds.20852","article-title":"Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease","volume":"21","author":"Garcia Ruiz","year":"2006","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.020_bib71","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.2003.034843","article-title":"Apomorphine in idiopathic restless legs syndrome: an exploratory study","volume":"76","author":"Tribl","year":"2005","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2016.11.020_bib72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2015.11.013","article-title":"Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients","volume":"23","author":"Borgemeester","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2016.11.020_bib73","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/1531-8257(200001)15:1<167::AID-MDS1029>3.0.CO;2-8","article-title":"Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease","volume":"15","author":"Factor","year":"2000","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2016.11.020_bib74","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1517\/14656566.9.4.523","article-title":"Treatment options for non-motor symptoms in late-stage Parkinson's disease","volume":"9","author":"Coelho","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.parkreldis.2016.11.020_bib75","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mds.23406","article-title":"Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study","volume":"26","author":"Dellapina","year":"2011","journal-title":"Mov. Disord."},{"issue":"8626\u20138627","key":"10.1016\/j.parkreldis.2016.11.020_bib76","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(88)90932-4","article-title":"Role of subcutaneous apomorphine in parkinsonian voiding dysfunction","volume":"2","author":"Christmas","year":"1988","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.parkreldis.2016.11.020_bib77","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/nau.1930120302","article-title":"Effects of apomorphine and L-dopa on the parkinsonian bladder","volume":"12","author":"Aranda","year":"1993","journal-title":"Neurourol. Urodyn."},{"issue":"5","key":"10.1016\/j.parkreldis.2016.11.020_bib78","first-page":"1890","article-title":"Suppression of bladder overactivity by adenosine A2A receptor antagonist in a rat model of Parkinson disease","volume":"187","author":"Kitta","year":"2012","journal-title":"J\u00a0Urol."},{"issue":"8","key":"10.1016\/j.parkreldis.2016.11.020_bib79","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/nau.22237","article-title":"Bladder dysfunction in advanced Parkinson's disease","volume":"31","author":"Winge","year":"2012","journal-title":"Neurourol. Urodyn."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2016.11.020_bib80","first-page":"144","article-title":"An audit of apomorphine in the management of complex idiopathic Parkinson's disease in Ireland","volume":"27","author":"Magennis","year":"2012","journal-title":"Mov. Disord."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2016.11.020_bib81","first-page":"366","article-title":"Assessment of impulse control disorders in Parkinson's patients with infusion therapies: a single center experience","volume":"28","author":"Todorova","year":"2013","journal-title":"Mov. Disord."},{"issue":"2\u20133","key":"10.1016\/j.parkreldis.2016.11.020_bib82","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.baga.2015.05.003","article-title":"Impulse control dysfunction and dopamine agonist withdrawal syndrome in Genetic Parkinson's: a case report","volume":"5","author":"Todorova","year":"2015","journal-title":"Basal Ganglia"},{"issue":"12","key":"10.1016\/j.parkreldis.2016.11.020_bib83","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","article-title":"Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs","volume":"174","author":"Moore","year":"2014","journal-title":"JAMA Intern Med."},{"issue":"4","key":"10.1016\/j.parkreldis.2016.11.020_bib84","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/syn.21805","article-title":"Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors","volume":"69","author":"Seeman","year":"2015","journal-title":"Synapse"},{"issue":"2","key":"10.1016\/j.parkreldis.2016.11.020_bib85","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/mds.870080208","article-title":"Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years","volume":"8","author":"Hughes","year":"1993","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2016.11.020_bib86","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/mds.10281","article-title":"Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients","volume":"17","author":"Manson","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.11.020_bib87","doi-asserted-by":"crossref","unstructured":"H.L. Tyne, J. Parsons, A. Sinnott, S.H. Fox, N.A. Fletcher, M.J. Steiger, A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease, J. Neurol. 251(11) (204) 1370-1374.","DOI":"10.1007\/s00415-004-0547-4"},{"issue":"Suppl 5","key":"10.1016\/j.parkreldis.2016.11.020_bib88","first-page":"1","article-title":"Guidelines for Parkinson's disease in the clinical practice","volume":"4","author":"Aguilar","year":"1999","journal-title":"Neurologia"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802016304680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802016304680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T18:47:02Z","timestamp":1657997222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802016304680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":88,"alternative-id":["S1353802016304680"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2016.11.020","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of apomorphine \u2013 A non-motor perspective","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2016.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}